We're also deeply committed to helping patients get access to our medicines." The approvals of Orkambi and Kalydeco paid off big time for Vertex shareholders: the company's stock tripled between 2012 and the end of last year to more than $130 a share. But Kalmar points out that Vertex has since made significant changes to its executive compensation policy, revealing in its 2016 proxy statement that equity awards will no longer be based on a targeted number of shares, but rather on a target value that will be based on several factors, including performance.